News and reporting on cell-free DNA testing.
Shares of Illumina fell in afternoon trading on the Nasdaq following a brief rise after the market open.
In its IPO prospectus, the company shared plans to broaden the use of its methylation technology from cancer screening to diagnostics and residual disease monitoring.
The company is selling 4,166,666 shares of its common stock at a price of $60 per share in the offering, which is expected to close Sept. 15.
A new study aims to compare the detection performance of Helio Health's circulating tumor DNA assay with that of other screening modalities.
The firm also expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million worth of shares of its common stock.
